Pfizer
-
A 70-year relay to end the dilemma of no quality treatment for thyroid eye disease patients in China
This is an inspiring story of drug development for patients in great need
-
Potential losses exceed $300 billion! Nearly 200 drugs are facing a patent cliff
For more reports, please follow DrugTimes
-
Split! Sanofi may book $16.4 billion
For more reports, please follow DrugTimes. Many thanks!
-
【重磅新闻】辉瑞决定全球下架镰状细胞病药物Oxbryta，因为数据审查显示死亡和并发症增加
药时代将继续关注，跟踪报道
-
Former Pfizer employees bravely venture into the red ocean of obesity drugs
Ambrosia, like Pfizer, is optimistic about the direction of oral small molecules, but whether it can surpass the front runners is something that still needs more time to verify
-
Try again! Pfizer ‘revives’ its oral GLP-1RA
DrugTimes will present more reports. Please stay tuned
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
